Reckitt Benckiser (RB) Given a GBX 7,020 Price Target by Goldman Sachs Analysts

Reckitt Benckiser (LON:RB) has been assigned a GBX 7,020 ($100.52) price objective by equities researchers at Goldman Sachs in a research report issued on Friday. The firm presently has a “neutral” rating on the stock. Goldman Sachs’ target price points to a potential upside of 27.38% from the stock’s current price.

Several other equities analysts have also weighed in on RB. JPMorgan Chase set a GBX 7,500 ($107.39) target price on shares of Reckitt Benckiser and gave the company a “buy” rating in a report on Wednesday, January 3rd. Kepler Capital Markets reduced their price target on shares of Reckitt Benckiser from GBX 7,300 ($104.52) to GBX 7,000 ($100.23) and set a “hold” rating on the stock in a research note on Monday, January 8th. Morgan Stanley set a GBX 9,000 ($128.87) price target on shares of Reckitt Benckiser and gave the company a “buy” rating in a research note on Tuesday, January 9th. UBS set a GBX 7,000 ($100.23) price target on shares of Reckitt Benckiser and gave the company a “neutral” rating in a research note on Thursday, January 11th. Finally, Liberum Capital reissued a “buy” rating and issued a GBX 8,000 ($114.55) price target on shares of Reckitt Benckiser in a research note on Monday, January 15th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of GBX 7,132.17 ($102.12).

How to Become a New Pot Stock Millionaire

LON:RB opened at GBX 5,511 ($78.91) on Friday. Reckitt Benckiser has a 1-year low of GBX 5,562 ($79.64) and a 1-year high of GBX 8,110.43 ($116.13).

TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/20/reckitt-benckiser-rb-given-a-gbx-7020-price-target-by-goldman-sachs-analysts.html.

Reckitt Benckiser Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Analyst Recommendations for Reckitt Benckiser (LON:RB)

Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply